Lopid Lowers High Triglycerides and Reduces Cardiovascular Risk
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.34 | $70.29 (0%) | 🛒 Add to cart |
| 60 | $1.71 | $140.58 $102.42 (27%) | 🛒 Add to cart |
| 90 | $1.51 | $210.87 $135.56 (36%) | 🛒 Add to cart |
| 120 | $1.39 | $281.16 $166.69 (41%) | 🛒 Add to cart |
| 180 | $1.29 | $421.74 $232.96 (45%) | 🛒 Add to cart |
| 270 | $1.22 | $632.62 $330.37 (48%) | 🛒 Add to cart |
| 360 | $1.18
Best per pill | $843.49 $425.76 (50%) | 🛒 Add to cart |
Synonyms | |||
Lopid (gemfibrozil) is a lipid-regulating agent, specifically a fibric acid derivative, indicated as an adjunct to diet and other therapeutic measures for the treatment of very high serum triglyceride levels in adult patients. It is a well-established medication in the management of dyslipidemia, particularly for patients with hypertriglyceridemia who are at significant risk of pancreatitis and for whom dietary intervention has proven insufficient. By modulating lipid metabolism in the liver, Lopid effectively reduces the hepatic production of triglycerides and increases the clearance of triglyceride-rich lipoproteins from the plasma. Its clinical use is supported by decades of evidence demonstrating efficacy in specific patient populations.
Features
- Active Ingredient: Gemfibrozil 600 mg
- Drug Class: Fibric acid derivative (fibrate)
- Administration: Oral tablet
- Mechanism of Action: Activates peroxisome proliferator-activated receptor-alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma.
- Bioavailability: Well-absorbed from the gastrointestinal tract.
- Half-life: Approximately 1.5 hours.
- Primary Excretion: Renal (approximately 70%)
Benefits
- Significant Reduction in Triglyceride Levels: Clinically proven to lower very high serum triglyceride levels, often by 40-60%, thereby reducing the immediate risk of acute pancreatitis.
- Favorable HDL-C Modulation: Increases high-density lipoprotein cholesterol (HDL-C or “good” cholesterol) levels, which is associated with a reduced risk of atherosclerotic cardiovascular disease.
- Cardiovascular Risk Reduction in Select Patients: Demonstrated in major clinical trials to reduce the incidence of coronary heart disease events in a specific cohort of middle-aged men with dyslipidemia.
- Adjunct to Lifestyle Modifications: Provides a powerful pharmacological tool to complement diet, exercise, and weight loss strategies for comprehensive lipid management.
- Well-Established Safety Profile: Has a long history of clinical use, with a well-characterized and generally manageable side effect profile when used as directed.
Common use
Lopid is primarily prescribed for the management of severe hypertriglyceridemia (Fredrickson type IV and V hyperlipidemia) in adult patients. Its most critical indication is to prevent episodes of acute pancreatitis, a serious and painful inflammatory condition of the pancreas that can be triggered by extremely high levels of triglycerides in the blood. It is also used to manage mixed dyslipidemia (elevated triglycerides with low HDL-C) and may be considered, based on historic trial data, for reducing the risk of coronary heart disease in a specific patient profile: middle-aged male patients with type IIb hyperlipidemia (elevated LDL-C and triglycerides with low HDL-C) who have not responded adequately to weight loss, dietary therapy, exercise, and other pharmacologic agents like statins. It is not typically a first-line agent for isolated high LDL-C.
Dosage and direction
The recommended adult dosage is 600 mg tablet administered orally twice daily, 30 minutes before the morning and evening meals. Adherence to the pre-meal timing is important for optimal absorption. Dosage should be individualized based on patient response and lipid levels, which should be monitored periodically. Therapy should not be initiated until other contributing factors to hypertriglyceridemia (such as poorly controlled diabetes, hypothyroidism, or certain medications) have been addressed. If an adequate response is not obtained within three months, therapy should be withdrawn.
Precautions
- Liver Function: Periodic liver function tests should be performed during therapy, as Lopid may cause abnormal elevations in transaminases (ALT, AST). Therapy should be terminated if these levels persist at significantly abnormal values.
- Cholelithiasis: Lopid may increase cholesterol excretion into the bile, potentially leading to the formation of gallstones. Patients should be monitored for signs of cholelithiasis.
- Hematologic Effects: Mild hemoglobin, hematocrit, and white blood cell decreases have been observed. Periodic blood counts are recommended during the first year of treatment.
- Musculoskeletal Effects: Myositis (muscle inflammation), characterized by muscle pain, tenderness, or weakness, has been reported. Patients should be advised to report any unexplained muscle symptoms promptly.
- Renal Impairment: Use with caution in patients with renal impairment, as the drug is primarily renally excreted. Dosage adjustment may be necessary.
- Pregnancy and Lactation: Lopid is not recommended for use during pregnancy (Category C) or by nursing mothers.
Contraindications
Lopid is contraindicated in patients with:
- Hypersensitivity to gemfibrozil or any component of the formulation.
- Pre-existing gallbladder disease.
- Hepatic or severe renal dysfunction, including primary biliary cirrhosis.
- Concurrent use with repaglinide or simvastatin due to a significantly increased risk of severe drug interactions, including rhabdomyolysis.
Possible side effect
The most common side effects are gastrointestinal in nature and often subside with continued treatment. A comprehensive, though not exhaustive, list includes:
- Common (>1%): Dyspepsia (indigestion), abdominal pain, epigastric pain, nausea, vomiting, diarrhea, constipation, flatulence.
- Less Common: Headache, dizziness, vertigo, fatigue, eczema, rash, pruritus (itching).
- Serious (Require immediate medical attention): Signs of myositis/rhabdomyolysis (unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise), signs of hepatitis (jaundice, upper right abdominal pain, dark urine), severe abdominal pain suggestive of pancreatitis or cholelithiasis, signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat).
Drug interaction
Lopid has a significant potential for drug interactions due to its effects on metabolic enzymes. Key interactions include:
- Statins (especially Simvastatin): Concomitant use increases the risk of severe myopathy or rhabdomyolysis. This combination is generally contraindicated.
- Repaglinide: Concomitant use is contraindicated due to a significant increase in repaglinide exposure and risk of severe hypoglycemia.
- Warfarin: Lopid may potentiate the anticoagulant effect of warfarin, significantly increasing the risk of bleeding. Prothrombin time (INR) should be monitored closely and warfarin dosage adjusted accordingly.
- CYP2C8/CYP2C9 Substrates: Lopid can inhibit the metabolism of drugs metabolized by these enzymes (e.g., pioglitazone, rosiglitazone, phenytoin), increasing their plasma concentrations and potential toxicity.
- Bile Acid Sequestrants (e.g., cholestyramine): These agents can bind to Lopid in the GI tract, impairing its absorption. Doses should be spaced at least 2 hours apart.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not take a double dose to make up for the missed one. Maintaining a consistent dosing schedule is important for therapeutic efficacy.
Overdose
There is no specific antidote for Lopid overdose. Symptomatic and supportive care is the mainstay of treatment. Since Lopid is highly protein-bound, dialysis is not likely to be effective. In cases of overdose, the patient should seek immediate medical attention or contact a poison control center. Symptoms may be an exaggeration of known adverse effects, particularly gastrointestinal upset.
Storage
Store Lopid tablets at room temperature, between 20°C to 25°C (68°F to 77°F), in a tightly closed container. The medication must be kept out of reach of children and pets. Protect from moisture, light, and excessive heat. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed through a medicine take-back program.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various sources believed to be accurate but cannot be guaranteed. The manufacturer’s official prescribing information is the ultimate authority.
Reviews
- Clinical Efficacy (4.5/5): “As a lipidologist, I reserve Lopid for patients with severe hypertriglyceridemia refractory to diet. The reduction in triglyceride levels is often dramatic and crucial for pancreatitis prevention. Its effect on raising HDL is also a valuable benefit in the right patient profile.” – Dr. A., Specialist
- Tolerability (3.8/5): “Most of my patients tolerate it well long-term. The initial GI side effects are common but usually transient. The major consideration is always vigilance for drug interactions, particularly with statins, which requires careful patient education.” – Clinical Pharmacist
- Patient Experience (4.0/5): “After struggling with dangerously high triglycerides, my doctor put me on Lopid alongside a strict diet. My numbers dropped into a safe range within months. I had some stomach upset at first, but it went away. I feel reassured knowing my risk of pancreatitis is now much lower.” – Verified Patient